Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia.

@article{Falloon1994PharmacokineticsAS,
  title={Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia.},
  author={Judith Falloon and Jonathon Lavelle and D Ogata-Arakaki and A Byrne and Alessandro Graziani and Alan V. Morgan and Michael A. Amantea and Kristin K. Ownby and Michael A. Polis and Richard T. Davey},
  journal={Antimicrobial agents and chemotherapy},
  year={1994},
  volume={38 7},
  pages={
          1580-7
        }
}
The safety and pharmacokinetics of weekly dapsone and weekly dapsone plus pyrimethamine were examined in adult patients with human immunodeficiency virus infection who were at risk for pneumocystis pneumonia because of a prior episode or a CD4+ T-cell count less than 250 cells per mm3. Groups of patients received 100, 200, and 300 mg of dapsone as a single weekly dose. The maximum tolerated dose of weekly dapsone was established as 200 mg per week in patients receiving at least 500 mg of… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-4 OF 4 CITATIONS

Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients.

VIEW 5 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Efficacy of once-weekly dapsone dosing for Pneumocystis jirovecii pneumonia prophylaxis post transplantation.

VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review.

  • Walter T. Hughes
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1998